Literature DB >> 16710358

Unraveling MCL-1 degradation.

J T Opferman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16710358     DOI： 10.1038/sj.cdd.4401978

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN： 1350-9047            Impact factor:   15.828


× No keyword cloud information.
  40 in total

1.  ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2.

Authors:  Rosa Martín-Pérez; Maho Niwa; Abelardo López-Rivas
Journal:  Apoptosis       Date:  2012-04       Impact factor: 4.677

Review 2.  Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members.

Authors:  Joseph T Opferman
Journal:  FEBS J       Date:  2015-09-15       Impact factor: 5.542

Review 3.  The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.

Authors:  Daniel E Johnson
Journal:  Endocr Relat Cancer       Date:  2014-03-21       Impact factor: 5.678

4.  Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.

Authors:  Rongqing Pan; Vivian R Ruvolo; Jun Wei; Marina Konopleva; John C Reed; Maurizio Pellecchia; Michael Andreeff; Peter P Ruvolo
Journal:  Blood       Date:  2015-06-04       Impact factor: 22.113

5.  Mitochondrion-dependent N-terminal processing of outer membrane Mcl-1 protein removes an essential Mule/Lasu1 protein-binding site.

Authors:  Matthew R Warr; John R Mills; Mai Nguyen; Stephanie Lemaire-Ewing; Jason Baardsnes; Karen L W Sun; Abba Malina; Jason C Young; Danny V Jeyaraju; Maureen O'Connor-McCourt; Luca Pellegrini; Jerry Pelletier; Gordon C Shore
Journal:  J Biol Chem       Date:  2011-05-25       Impact factor: 5.157

6.  Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.

Authors:  Katelyn G Ponder; Shannon M Matulis; Sadae Hitosugi; Vikas A Gupta; Cathy Sharp; Francis Burrows; Ajay K Nooka; Jonathan L Kaufman; Sagar Lonial; Lawrence H Boise
Journal:  Cancer Biol Ther       Date:  2016-07-02       Impact factor: 4.742

7.  Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy.

Authors:  Rongqing Pan; Vivian Ruvolo; Hong Mu; Joel D Leverson; Gwen Nichols; John C Reed; Marina Konopleva; Michael Andreeff
Journal:  Cancer Cell       Date:  2017-12-11       Impact factor: 31.743

8.  Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression.

Authors:  Kristen E Olberding; Xiaoli Wang; Yanglong Zhu; Jianmin Pan; Shesh N Rai; Chi Li
Journal:  Cancer Biol Ther       Date:  2010-11-01       Impact factor: 4.742

9.  Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.

Authors:  Changyou Li; Rongxiu Li; Jennifer R Grandis; Daniel E Johnson
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

10.  Monosaccharide digitoxin derivative sensitize human non-small cell lung cancer cells to anoikis through Mcl-1 proteasomal degradation.

Authors:  Varisa Pongrakhananon; Todd A Stueckle; Hua-Yu Leo Wang; George A O'Doherty; Cerasela Zoica Dinu; Pithi Chanvorachote; Yon Rojanasakul
Journal:  Biochem Pharmacol       Date:  2013-11-11       Impact factor: 5.858
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.